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Abstract 
Background 
Adolescents with cancer are enrolled in clinical trials at far lower rates than children. 
This report compares the number of adolescents (15–19-year-olds) and children (0–
14-year-olds) enrolled in the protocols of the European pediatric Soft tissue sarcoma 
Study Group (EpSSG) with the number of cases expected to occur. 
Methods 
The observed-to-expected (O/E) ratio was detected in the EpSSG countries 
contributing most of the cases, that is, Italy, France, Spain, the Netherlands, United 
Kingdom, and Ireland. The observed cases included patients enrolled in any of the 
EpSSG protocols from October 2008 to October 2015, when all EpSSG protocols 
were open in these countries. The number of expected cases was calculated from 
the incidence rates estimated throughout the RARECAREnet database in the 
countries’ population-based cancer registries. 
Results 
In the countries considered, 2,118 cases aged 0–19 years were enrolled in the 
EpSSG trials from 2008 to 2015: 82.8% were children and 17.2% were adolescents. 
The O/E ratio was 0.30 among patients 15–19 years old, as opposed to 0.64 for 
those 0–14 years old. The O/E ratio differed for the different subtypes: in 
adolescents, it was 0.64 and 0.18 for rhabdomyosarcoma (RMS) and non-
rhabdomyosarcoma soft tissue sarcomas (NRSTS), respectively; in children, it was 
0.77 and 0.50, respectively. The O/E ratios differed across the countries considered. 
Conclusions 
Adolescents were less well represented than children on the EpSSG protocols, with 




Adolescents with cancer form a subgroup of patients whose optimal clinical 
management and best possible access to care remain a challenge. It has been 
frequently reported that adolescents with cancer are enrolled in clinical trials at far 
lower rates than children,[1] and it has been suggested that this is one of the 
reasons why adolescents with certain tumor types have worse survival rates than 
children with the same disease.[2, 3] Such age-related differences in survival have 
been described for soft tissue sarcomas (STS),[4-8] a group of tumors occurring in 
children and adolescents, as well as adults. The recent EUROCARE-5 study 
reported 5-year survival rates of 66.6% among patients 0–14 years of age with 
rhabdomyosarcoma (RMS) diagnosed between 2000 and 2007, as opposed to 
39.6% for patients 15–19 years of age.[9] This finding is likely multifactorial; clinical 
trial participation, as well as biological factors, may have an impact. 
The European pediatric Soft tissue sarcoma Study Group (EpSSG) is an 
international cooperative dedicated to conducting clinical studies and promoting 
research on STS in children and adolescents. It was jointly established in 2005 by 
the International Society of Pediatric Oncology—Malignant Mesenchymal Tumor 
Committee (SIOP-MMT) and the Italian Pediatric Oncology Association 
(Associazione Italiana Ematologia Oncologia Pediatrica [AIEOP]—Soft Tissue 
Sarcoma Committee, originally called the Italian Cooperative Group [ICG]). The 
EpSSG activated four clinical trials for newly diagnosed patients up to 21 years of 
age with STS (RMS and non-rhabdomyosarcoma soft tissue sarcomas [NRSTS]) 
over a 10-year period ending in 2015. 
The present report compares the number of adolescents (defined as patients 15 to 
19 years old) and children (0–14 years old) enrolled in the EpSSG's protocols with 
the number of adolescent cases expected to occur, estimated from the incidence 




The analysis of observed-to-expected ratios (O/E) for newly diagnosed cases of 
RMS and NRSTS in children and adolescents was done for patients 0–19 years of 
age. The EpSSG studies cover 15 different countries and 131 centers, but our 
analysis focused on the five datasets contributing most of the cases (more than 
85%), that is, Italy, France, the dataset from United Kingdom (UK) and Ireland 
(considered together for the purposes of this analysis), Spain, and the Netherlands. 
The observed cases included patients enrolled in any of the four EpSSG protocols 
from October 1, 2008 to October 1, 2015 (Table 1), a time period chosen because all 
four EpSSG studies were open in the countries noted above. 
The number of expected cases was estimated from the STS incidence rates in the 
countries’ population-based cancer registries. Age-specific incidence rates (for the 
age groups: 0–4, 5–9, 10–14, and 15–19 years) were calculated in each country for 
the years 2000–2007 and then multiplied by the corresponding population figures. 
The RARECAREnet (www.rarecarenet.eu) database was used to estimate the 
incidence rates. The population coverage of the registries varied across age groups 
and countries. For children, it was 40% in Italy, 37% in Spain, and 100% in France, 
UK plus Ireland, and the Netherlands. For adolescents, it was 30% in Italy, 15% in 
Spain, 12% in France, and 100% in UK plus Ireland, and the Netherlands. The 
population considered when estimating the number of expected cases was drawn 
from the EUROSTAT database,[10] and the period considered was 2009–2015, that 
is, much the same as for the observed cases. The population figures for 2015 were 
still unavailable in the EUROSTAT database at the time of the study, so the 2014 
figures were used instead. 
Ninety-five percent confidence intervals (CIs) were calculated for the O/E ratio, 
assuming a Poisson distribution of the observed cases with the mean and variance 




In the countries considered, there were 2,118 cases of STS in patients aged 0–19 
years enrolled in the EpSSG trials from October 2008 to October 2015: 1,754 
(82.8%) were 0–14 years old and 364 (17.2%) were aged 15–19. The number of 15–
19-year-olds remained stable throughout the study period (with 46–54 cases/year, 
median 48). By histotype, 1,340 enrolled cases were RMS (63.3%) and 778 were 
NRSTS (36.7%), with more cases of RMS than of NRSTS being observed in both 
children (RMS accounted for 65% of the cases) and adolescents (RMS cases were 
55%). Regarding the expected cases, the epidemiologic data suggested that NRSTS 
should account for 54.2% of all STS (45.3% in children and 74.1% in adolescents). 
The O/E ratio for all STS among patients 15–19 years of age was 0.30 (95% CI 
0.27–0.33), as opposed to 0.64 (95% CI 0.61–0.68) for children up to 14 years of 
age. As shown in Table 2, the O/E ratio differed for the different STS subtypes. In 
adolescents, it was 0.64 (95% CI 0.55–0.73) and 0.18 (95% CI 0.15–0.21) for RMS 
and NRSTS, respectively; in children, it was 0.77 (95% CI 0.72–0.81) and 0.50 (95% 
CI 0.46–0.54), respectively. In the group with NRSTS, synovial sarcoma was the 
most common histotype (with 134 cases observed: 98 in children and 36 in 
adolescents). The O/E ratio for synovial sarcoma was 0.66 for children and 0.31 for 
adolescents. 
The results differed across the countries considered. The percentages of adolescent 
cases recruited by the EpSSG protocols were 23.1 in Italy, 15.1 in France, 14.9 in 
UK and Ireland, 8.7 in Spain, and 21.0 in the Netherlands. Table 3 shows the O/E 
ratios for the different countries: the O/E ratio was always lower for adolescents than 




This report analyzed the accrual rate of patients with STS by age in European 
pediatric trials from October 2008 to October 2015. While the study showed a 
satisfactory enrollment rate for children, especially those with RMS, it demonstrated 
that adolescents were less represented in EpSSG protocols, even though they were 
open to patients up to 21 years of age. 
While there is no question that clinical trials are a fundamental part of cancer 
research, benefiting subsequent generations of patients and furthering our scientific 
knowledge, it remains unclear whether participating in clinical trials improves survival 
on an individual level. However, there is some indirect evidence to suggest a positive 
effect of such trials on participants’ outcomes, however (e.g., a better quality of care 
thanks to the involvement of a broader group of highly specialized professionals 
and/or to the stricter process control demanded by clinical protocols).[1, 11, 12] 
It has often been said that adolescents with cancer are a medically underserved 
population and their limited participation in clinical protocols is widely acknowledged. 
Various studies reported that the proportion of adolescent patients entering clinical 
protocols ranged from 5 to 34%.[13-19] 
Our results confirm the discrepancy in the rates of access to clinical protocols for 
STS between adolescents and children, albeit with some important differences 
depending on the STS subtypes involved. The O/E ratio for adolescents with RMS 
was much higher than for NRSTS and superior to that reported in previous studies 
(0.27 in the Italian AIEOP analysis in the 1988–2005 period).[4] RMS is a pediatric-
type tumor generally managed by pediatric oncologists,[5, 6] likely prompting 
preferential referral to pediatric centers and facilitating inclusion in clinical trials. In 
fact, the pattern of initial referral may have a marked influence on whether or not 
young patients access clinical trials. Because NRSTS are mainly adult-type tumors, 
adolescents with this type of cancer are more likely to be referred to adult (or 
orthopedic) wards, even when they are very young. It is beyond the scope of this 
study to discuss the adequacy of this approach, balancing the advantages of the 
care providers’ expertise against the particular psychosocial needs of adolescent 
patients, and the value of age-appropriate inhospital facilities.[20, 21] 
Adolescent STS patients might not be included in EpSSG trials either because they 
are referred to adult oncology centers (as mentioned above), or because, even when 
they are admitted to pediatric oncology units, the centers involved do not enroll them 
in the EpSSG protocol. In other words, a part of the difference in the EpSSG O/E 
ratios for children and adolescents with NRSTS vis-à-vis RMS may be attributable to 
pediatric oncologists taking a different attitude to the inclusion of the former in their 
clinical protocols. Judging from their incidence, NRSTS should account for more than 
one in two cases of STS occurring in 0–19-year-olds, but the proportion in the 
EpSSG registry was 36.7%. It is worth noting that the O/E ratio was higher for 
synovial sarcoma than for other NRSTS, possibly because pediatric oncologists 
have always tended to consider it as an RMS-like tumor and have gained 
considerable experience caring for it.[22] Another reason for the low accrual rate to 
the EpSSG trial for NRSTS may be that for some patient subgroups the treatment 
protocol required surgery alone (or surgery plus radiotherapy) and some clinicians 
might see no advantage to register patients treated with surgery only. In any case, 
EpSSG centers should improve their capability for treating NRSTS patients, also 
because the countries concerned have no other protocols competing with the 
EpSSG that might enroll patients under 18 years of age. 
Another part of our analysis concerns the differences identified in the countries 
considered. These differences relate to national policies and how cancer treatment 
for adolescents and young adults (AYAs) is organized in each country, but also to 
differences in the way a given country's pediatric centers cooperate on STS. While in 
many countries the EpSSG protocols involve the majority of the pediatric oncology 
centers, in Spain, for example (where a discrepancy in the O/E ratios emerged for 
children as well as adolescents), many pediatric oncology centers have not become 
involved in the EpSSG. 
ational programs dedicated to AYAs have been developed across Europe in recent 
years.[23] The UK pioneered these projects, developing several age-specific units 
and healthcare policy directives. It has particularly focused on a strategy to increase 
AYA enrollment in clinical protocols.[19] Our present findings suggest, however, that 
further efforts are needed in this direction (only one in four British adolescents with 
STS were included in the EpSSG protocols, for instance). National/international AYA 
programs should increase the exchanges with the disease-specific cooperative 
groups running clinical trials. For example, changing the eligibility criteria concerning 
age (raising the cutoff for pediatric protocols, or admission to pediatric wards,[24] or 
opening adult protocols to pediatric patients[25]) may prove useless without closer 
links between the parties developing the trials. In fact, the EpSSG only considered 
pediatric oncology groups and institutions—no adult centers or adult groups dealing 
with STS—despite raising the age limit for participation in their trials to 21 years. 
Much the same could be said about the policies to set up dedicated units with age-
appropriate facilities: providing dedicated spaces or recreational events and age-
specific psychosocial support becomes pointless if such units are not closely linked 
with the groups running clinical protocols and patients are unable to enter age-
appropriate clinical trials. 
The findings reported here (especially regarding individual countries) may suffer from 
several limitations. First, the RARECAREnet database did not cover all countries 
equally well due to variation in the implementation of cancer registration across 
Europe. The extent to which a population sampled by a regional registry is 
representative of a country as a whole depends on the differences and similarities in 
the national population's socioeconomic status. Rather than comparing different 
countries, our data should be considered for all five countries together (pooled data 
are less likely to be biased). Another limitation of our study lies in the fact that the 
incidence rates estimated for adolescents are based on a limited number of cases, 
and this could lead to fluctuations in the figures that would have an impact on the 
O/E ratios. The 95% CIs give an indication of the likely range of values for the O/E 
ratios and should be taken into account in order to interpret the figures properly. It is 
worth noting that the incidence rates for children and adolescents (for RMS and 
NRSTS) did not differ across the considered countries and were comparable with 
those previously described in Europe and in international studies.[26-28] Similarly, 
no major differences in the incidence rate were seen for RMS between the EpSSG 
countries and the United States (as reported for by the Surveillance, Epidemiology, 
and End Results [SEER] Program), while the incidences of NRSTS in Europe were 
lower than that reported by the SEER.[29] 
In conclusion, our study represents just the pediatric view of the access to care of 
adolescents with STS. No data are available on where and how the adolescents not 
admitted to the EpSSG centers were treated, or on the survival of the patients 
treated in the EpSSG trials compared with those treated elsewhere. However, the 
main message of the study is that adolescents’ access to clinical trials is still a 















Table 3. Crude incidence rate (IR) per 1,000,000, observed cases, expected cases, 
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